AI-generated analysis. Always verify with the original filing.
Tonix Pharmaceuticals Holding Corp. announced on March 26, 2026, that the first participant was dosed in a Phase 1 investigator-initiated study evaluating TNX-1900 (intranasal potentiated oxytocin) on trigeminal nerve-mediated vasodilation of the forehead, a model for trigeminal neurovascular reactivity in healthy female volunteers. The study, led by Dr. Antoinette Maassen van den Brink at Erasmus University Medical Center, assesses TNX-1900's potential for migraine and craniofacial pain via a distinct pathway from CGRP inhibitors.
Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Ac
Other Events. On March 26, 2026, the Company announced that the first participant was dosed in a Phase 1 investigator-initiated study to evaluate the effect of
Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 Press Release of the Company, March 26, 2026 104 Cover Page Interactive Data File (embedde